| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2002-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_515fb23572eb0c0b054fe85b6abef9d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8d60700f03f04e9ffa14d5cc01e9ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21de6793e990ea4ef4e3d0db4066002b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78927d29f707b8b8fd280ad12b4dca6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b533eca8630d292889f15427dbce4263
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cead874c44fd845e6efa5579c3dce019 |
| publicationDate |
2002-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2439690-A1 |
| titleOfInvention |
Modified interferon alpha with reduced immunogenicity |
| abstract |
The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for th e polypeptide to elicit an immune response upon administration to the human subject. The invention in particular to the modification of human interferon alpha and specifically interferon alpha 2(INF.alpha.2) to result in proteins that are substantially non-immunogenic or less immunogenic than any non- modified counterpart when use in vivo. |
| priorityDate |
2001-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |